Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL): Update on Indications and Outcome - Enduring
CAR T-cells have altered the landscape of pediatric acute lymphoblastic leukemia (ALL) management. As this therapy is becoming more widespread, the intersecting roles of CAR T-cells and hematopoietic stem cell transplantation (HSCT) are evolving and frequent reevaluations of the indication and outcomes of pediatric ALL patients to both therapies are warranted. In July 2020, the American Society for Transplantation and Cellular Therapy (ASTCT) published updated guidelines to help providers navigate these decisions. The purpose of this lecture is to update pediatric oncologists on advances in hematopoietic stem cell transplantation (HSCT) by a leading expert in the field.
City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.
- Identify indications for hematopoietic stem cell transplantation (HSCT) and for CAR T-cells based on the current literature.
- Examine the status of the current literature, including pitfalls and weaker recommendations.
- Identify current outcomes for pediatric acute lymphoblastic leukemia (ALL) patients who undergo HSCT.
- Outline the various types of cultural diversities (gender, age, race, religion, culture, etc.) that relate to demographics, diagnosis and treatment.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Sajad Khazal has indicated that he does not have anything to disclose.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL): Update on Indications and Outcome - Enduring has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.25
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.25 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL): Update on Indications and Outcome - Enduring for a maximum of 1.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.
Current version of Edge, Firefox, Safari, or Chrome.